April 14, 2023 7:25am
The move follows the cell and gene therapy sector’s dramatic advance/decline line ascension as inflation could be slowing.
Always’ remember and do NOT forget, today’s investors’ gold is a trader’s disposable tin
Pre-open indications: 3 Sell into Strength, and 5 Negative Indications
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
The 8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday …
Dow futures are UP +0.09% or (+32 points), S&P futures are DOWN -0.05% or (-2 point) and NASDAQ futures are DOW -0.56% or (-74 points) early in the pre-open – so far
Stock futures slipped Friday,
European markets are higher,
Asia-Pacific markets mostly rise.
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
The three (3) major indexes ended up; as the Dow closed UP +383.19 points (+1.14%), the S&P closed UP +54.27 points (+1.33%) while the Nasdaq closed UP + 236.93 points (+1.99%).
“The movement in the market yesterday reflects the continued decline in inflationary pressures — and the belief, therefore, that the Fed will more likely stop with one more rate increase rather than two. Investors are becoming optimistic that times will improve.” <Sam Stovall, chief investment strategist at CFRA Research>
Thursday’s (4/13) … RegMed Investors’ (RMi) closing bell: “sector more than gains following inflation data release. Together with tailwinds and a cooler PPI. Always’ remember and do NOT forget, today’s investors’ gold is a trader’s disposable tin. Avrobio (AVRO) closed up Thursday +$0.07 to $0.96 after Wednesday -$0.06 to $0.89 and Tuesday’s +$0.04 – still under Nasdaq rule of $1.00; will it revisit the de-listing status after eight (8) sessions under the minimum?” … https://www.regmedinvestors.com/articles/12914
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … “The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth” … https://www.regmedinvestors.com/articles/12843 --- 31 of 35 (my coverage group)
Ebb and flow:
Q2/23 – 1 holiday, 3 positive close and 5 negative closes
Q1/23 –
· March – ended with 10 positive and 13 negative closes
· February – 1 holiday, 2 vacation, 7 negative and 8 positive closes
· January – 2 holidays, 11 positive and 9 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Sell into Strength:
Thursday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Beam Therapeutics (BEAM) closed up +$2.49 with a positive +$0.16 or +0.50% aftermarket indication
Caribou Biosciences (CRBU) closed up +$0.52 with a positive +$0.14 or +2.89% aftermarket indication
Editas Medicine (EDIT) closed up +$1.29 with a positive +$0.13 or +1.70% pre-open indication
Negative Indications:
Thursday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Intellia Therapeutics (NTLA) closed up +$4.53 with a negative -$0.05 or -0.13% pre-open indication
CRISPR Therapeutics CRSP) closed up +$7.09 with a negative -$0.26 or -0.51% aftermarket indication
Ionis Pharmaceuticals (IONS) closed up +$0.97 with a negative -$0.02 or -o.05% aftermarket indication,
Verve Therapeutics (VERV) closed up +$2.00 with a negative -$0.04 or -0.25% aftermarket indication
Voyager Therapeutics (VYGR) closed up +$0.27 with a negative -$0.16 or -1.98% aftermarket indication.
The BOTTOM LINE: I try to keep it simple and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
Thursday's sector’s action was a positive step.
I say it is “make a BUCK” Friday. I also don’t believe that investors should add exposure, assuming Thursday’s dramatic market trend higher. It wouldn't take much for the sector’s equities to decline once again.
Specifically, be ready to take profits; this is definitely not a time to be locked into a bullish mindset.
Reiterating, “A SUSTAINABLE uptrend is needed to get credibility BACK into the sector’s investment”
I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product.
And I can always be WRONG but, I am mostly EARLY!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
